Abstract
Tobacco addiction is one of the leading preventable causes of mortality in the world and nicotine appears to be the main critical psychoactive component in establishing and maintaining tobacco dependence. Several lines of evidence suggest that the rewarding effects of nicotine, which underlie its abuse potential, can be modulated by manipulating the endocannabinoid system. For example, pharmacological blockade or genetic deletion of cannabinoid CB1 receptors reduces or eliminates many behavioral and neurochemical effects of nicotine that are related to its addictive potential. This review will focus on the recently published literature about the role of the endocannabinoid system in nicotine addiction and on the endocannabinoid system as a novel molecular target for the discovery of medications for tobacco dependence.
Keywords: Addiction, tobacco dependence, nicotine, endocannabinoid system, CB1 receptors
CNS & Neurological Disorders - Drug Targets
Title: The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction
Volume: 7 Issue: 5
Author(s): Maria Scherma, Paola Fadda, Bernard Le Foll, Benoit Forget, Walter Fratta, Steven R. Goldberg and Gianluigi Tanda
Affiliation:
Keywords: Addiction, tobacco dependence, nicotine, endocannabinoid system, CB1 receptors
Abstract: Tobacco addiction is one of the leading preventable causes of mortality in the world and nicotine appears to be the main critical psychoactive component in establishing and maintaining tobacco dependence. Several lines of evidence suggest that the rewarding effects of nicotine, which underlie its abuse potential, can be modulated by manipulating the endocannabinoid system. For example, pharmacological blockade or genetic deletion of cannabinoid CB1 receptors reduces or eliminates many behavioral and neurochemical effects of nicotine that are related to its addictive potential. This review will focus on the recently published literature about the role of the endocannabinoid system in nicotine addiction and on the endocannabinoid system as a novel molecular target for the discovery of medications for tobacco dependence.
Export Options
About this article
Cite this article as:
Scherma Maria, Fadda Paola, Foll Le Bernard, Forget Benoit, Fratta Walter, Goldberg R. Steven and Tanda Gianluigi, The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction, CNS & Neurological Disorders - Drug Targets 2008; 7 (5) . https://dx.doi.org/10.2174/187152708786927859
DOI https://dx.doi.org/10.2174/187152708786927859 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polyphenol Supplementation as a Complementary Medicinal Approach to Treating Inflammatory Bowel Disease
Current Medicinal Chemistry Coal Mine Dust Lung Disease: The Silent Coal Mining Disaster
Current Respiratory Medicine Reviews The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism L-Arginine Signalling Potential in the Brain: The Peripheral Gets Central
Recent Patents on CNS Drug Discovery (Discontinued) A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Current Diabetes Reviews LDL and HDL Subfractions, Dysfunctional HDL: Treatment Options
Current Pharmaceutical Design Cardiometabolic Risk Related to the Association of hypertriglyceridemia-Low HDLc
Current Pharmaceutical Design Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA) – Animal Models as a Proof of Concept
Current Medicinal Chemistry Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Current Cardiology Reviews Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Infective Endocarditis Complicating Hypertrophic Obstructive Cardiomyopathy: Is Antibiotic Prophylaxis Really Unnecessary?
Current Cardiology Reviews Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Anti-Inflammatory and Pro-Resolving Effects of N-3 PUFA in Cancers: Structures and Mechanisms
Current Topics in Medicinal Chemistry Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Temporally and Spatially Restricted Gene Expression Profiling
Current Genomics A Comparison of Non-Human Primate Cytochrome P450 2D Members and the Implication in Drug Discovery
Current Drug Metabolism Effects of Imidazolic Agonism on Blood Pressure, Sympathetic Activity, Left Ventricular Hypertrophy and Insulin Resistance
Current Hypertension Reviews Editorial [Hot topic: Infective Endocarditis (Guest Editor: Ioannis Starakis)]
Infectious Disorders - Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery